Wednesday, March 20, 12:34 PM
iCAD (ICAD +2.3%) FDA) gains after saying it's received FDA clearance for its new cervical applicator for use with its Xoft Axxent Electronic Brachytherapy System to deliver high dose rate brachytherapy for intracavitary treatment of cancer of the uterus and cervix.
Comment![Healthcare, On the Move]
Friday, April 16, 2010, 11:32 AM
Image analysis firm iCAD (ICAD) +7.6% as FDA clearance may finally be near for its Veralook colonoscopy product. Usually a three-month process, the review has taken nearly a year at an overloaded FDA.